NCT03125460已完成不适用
Clinical Evaluation of Xpert Bladder Cancer Monitor for Monitoring the Recurrence of Bladder Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Cepheid
- 入组人数
- 424
- 试验地点
- 17
- 主要终点
- Comparison to histology for positive or suspicious cystoscopy
研究概览
简要总结
The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. The study is conducted at locations within and outside of the United States. Testing is performed on urine specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is ≥ 40 years of age
- •Subject has provided documented informed consent as required by the reviewing IRB or EC. Experimental Bill of Rights will be documented for all subjects enrolled in applicable states.
- •Subject is considered disease positive within 12 months (365 days) of enrollment.
- •At the time of the enrollment visit, the subject is scheduled for a standard of care cystoscopy which will be completed within 3 days of providing a urine specimen.
- •Subject has agreed to provide at least 60 mL of voided urine for study purposes at the enrollment visit.
- •Subject has agreed to provide at least 60 mL of voided urine for study purposes at each subsequent standard of care cystoscopy visit for at least 12 months (365 days) following enrollment if the subject will enter the Longitudinal cohort.
- •Any subject considered anticipatory positive at the initial visit shall be enrolled into the longitudinal cohort. For each anticipatory positive enrolled into the longitudinal cohort a random disease negative subject shall be enrolled.
- •Subject has been previously enrolled into the study.
- •Urine specimen to be used for study purposes is from the first morning void.
- •Subject has had an excision procedure within six weeks (42 days) of enrollment.
- •The subject is not scheduled for a standard of care cystoscopy visit within 12 months (365 days) following enrollment.
排除标准
- 未提供
结局指标
主要结局
Comparison to histology for positive or suspicious cystoscopy
时间窗: Follow up = 12 months from Subject Enrollment (Baseline)
Comparison to histology for positive or suspicious cystoscopy
次要结局
- Comparison to UroVysion and urine cytology(Follow up = 12 months from Subject Enrollment (Baseline))
研究者
研究点 (17)
Loading locations...
相似试验
已完成
不适用
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy UnitUrinary Bladder NeoplasmsNCT06281691Jørgen Bjerggaard Jensen127
已完成
不适用
Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation StudyBladder CancerNCT03715660Mansoura University198
已完成
不适用
Markers of Response to Intravesical Bladder Cancer TherapyBladder CancerNCT01007058M.D. Anderson Cancer Center150
已完成
不适用
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial CarcinomaBladder CancerNCT02647112Nucleix Ltd.1,050
尚未招募
不适用
Diagnosis of bladder cancer using probe-based confocal laser endomicroscopyBladder CancerJPRN-UMIN000021067Depatment of Urology, Kyoto Prefectural University of Medicine50